Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3D-959 in Mild to Moderate Alzheimer's Disease
NCT02560753Phase 2Completed
- Sponsor
- T3D Therapeutics
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of t3d-959 in Alzheimer's disease (AD), sponsored by T3D Therapeutics. Started Jul 2015; status: completed.
02
Drugs
t3d-959
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02560753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560753.